Filtered By:
Specialty: Cardiology
Drug: Activase

This page shows you your search results in order of date.

Order by Relevance | Date

Total 53 results found since Jan 2013.

Improvement of Functional Outcomes in Patients with Stroke who Received Alteplase for Over 15 Years: Japan Stroke Data Bank
CONCLUSIONS: We revealed that IVT implementation rates in patients with AIS increased, and the functional outcome in these patients improved over 15 years. Therefore, the Japanese IVT dissemination strategy is considered appropriate and effective.PMID:37587045 | DOI:10.5551/jat.64200
Source: Journal of Atherosclerosis and Thrombosis - August 16, 2023 Category: Cardiology Authors: Akiko Ishigami Kazunori Toyoda Michikazu Nakai Sohei Yoshimura Shinichi Wada Yusuke Sasahara Kazutaka Sonoda Kaori Miwa Junpei Koge Masayuki Shiozawa Yoshitaka Iwanaga Yoshihiro Miyamoto Jin Nakahara Norihiro Suzuki Shotai Kobayashi Kazuo Minematsu Masato Source Type: research

Middle Cerebral Artery Dissection: A Report of Two Cases With Treatments and Outcomes
Cureus. 2023 May 29;15(5):e39632. doi: 10.7759/cureus.39632. eCollection 2023 May.ABSTRACTIn the present report, we describe two cases of right-sided M1 segment middle cerebral artery dissection in a 51-year-old Asian female and in a 28-year-old Caucasian male patient with no previous history of ischemic stroke or known intracranial atherosclerosis presenting with acute unilateral headache progressing to severe multifocal hemispheric infarction with nearly complete one-sided motor paralysis. In both patients, a middle cerebral artery dissection was detected on angiography; they were given exclusively medical therapy: patie...
Source: Atherosclerosis - June 30, 2023 Category: Cardiology Authors: Giulio Papiri Stefano Bruni Emanuele Puca Sandro Sanguigni Matteo Marcucci Source Type: research

Biosimilar Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Real World Study
CONCLUSION: This present study observed no difference in the efficacy and safety between biosimilar TNK and rTPA. Our findings are in concordance with published trials showing equivalence between the two molecules.PMID:37034051 | PMC:PMC10081554 | DOI:10.4103/aian.aian_754_22
Source: Atherosclerosis - April 10, 2023 Category: Cardiology Authors: Ayush Mohan Snigdha Komakula Suhas Murali Pooja Anand Dyuti Shah V Y Vishnu Awadh Kishor Pandit Ayush Agarwal Deepti Vibha Mamta Bhushan Singh M V Padma Srivastava Rohit Bhatia Source Type: research

Tenecteplase Noninferior to Alteplase for Ischemic Stroke: TRACE-2 Tenecteplase Noninferior to Alteplase for Ischemic Stroke: TRACE-2
988192Medscape Medical News
Source: Medscape Cardiology Headlines - February 13, 2023 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Dual Antiplatelet Therapy Proves Mettle in Minor Stroke
(MedPage Today) -- DALLAS -- Dual antiplatelet therapy (DAPT) proved non-inferior to IV alteplase in Chinese patients with minor non-disabling stroke, a researcher reported. In the ARAMIS trial of patients with acute minor stroke who presented...
Source: MedPage Today Cardiovascular - February 13, 2023 Category: Cardiology Source Type: news

Tenecteplase on Par With Alteplase, Randomized Trial Affirms
(MedPage Today) -- DALLAS -- Tenecteplase (TNKase) did as good a job at ischemic stroke thrombolysis as did alteplase (Activase) for patients presenting within 4.5 hours of symptom onset in the randomized TRACE-2 trial from China. The proportion...
Source: MedPage Today Cardiovascular - February 9, 2023 Category: Cardiology Source Type: news

Intravenous Thrombolytics in the Treatment of Acute Ischemic Stroke
AbstractPurpose of ReviewTo review the current evidence and ongoing clinical trials evaluating the efficacy and safety of tenecteplase (TNK), an alternative tissue plasminogen activator (tPA), in the acute management of arterial ischemic stroke (AIS). To date, alteplase is the only tPA approved by the United States FDA for use in AIS.Recent FindingsThere have been multiple phase two and three trials investigating the safety and efficacy of TNK in AIS. In patients with AIS due to large vessel occlusion, one randomized controlled trial demonstrated superiority of TNK for vessel recanalization rates and long-term functional o...
Source: Current Treatment Options in Cardiovascular Medicine - January 2, 2023 Category: Cardiology Source Type: research

Outcomes with IV tenecteplase and IV alteplase for acute ischemic stroke with or without thrombectomy in real-world settings in the United States
J Stroke Cerebrovasc Dis. 2022 Dec 6;32(2):106898. doi: 10.1016/j.jstrokecerebrovasdis.2022.106898. Online ahead of print.NO ABSTRACTPMID:36493706 | DOI:10.1016/j.jstrokecerebrovasdis.2022.106898
Source: Atherosclerosis - December 9, 2022 Category: Cardiology Authors: Adnan I Qureshi William I Baskett Navpreet K Bains Brandi R French Farhan Siddiq Camilo R Gomez Chi-Ren Shyu Source Type: research

Combo Thrombolytic Approach Fails to Reduce ICH in Stroke Combo Thrombolytic Approach Fails to Reduce ICH in Stroke
The DUMAS study showed no benefit on the primary outcome of all ICH with low-dose alteplase followed by mutant pro-urokinase; but there were promising signs of a potential reduced bleeding risk.Medscape Medical News
Source: Medscape Cardiology Headlines - November 2, 2022 Category: Cardiology Tags: Cardiology News Source Type: news

ACT Tenecteplase Trial to Change Clinical Practice in Stroke? ACT Tenecteplase Trial to Change Clinical Practice in Stroke?
The largest trial so far conducted with the new bolus thrombolytic, tenecteplase, in acute ischemic stroke has shown noninferiority to alteplase with similar safety.Medscape Medical News
Source: Medscape Cardiology Headlines - May 5, 2022 Category: Cardiology Tags: Cardiology News Source Type: news